Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
intrauterine device
|
| gptkbp:activeDuring |
levonorgestrel
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Mirena
|
| gptkbp:clinicalTrials |
requires follow-up visits
may cause discomfort during insertion may improve menstrual symptoms studies show effectiveness studies show safety |
| gptkbp:contraindication |
pregnancy
mandatory reporting active pelvic infection uterine abnormalities |
| gptkbp:duration |
up to 5 years
|
| gptkbp:effectiveDate |
over 99%
|
| gptkbp:hasCapacity |
available resources
|
| gptkbp:healthcare |
informed consent required
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mirena
|
| gptkbp:lastProduced |
2000
|
| gptkbp:manufacturer |
gptkb:Bayer
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:United_States Europe |
| gptkbp:numberOfStudents |
in-office procedure
|
| gptkbp:offers |
varies by location
insurance may cover |
| gptkbp:percentageOfFamiliesBelowPovertyLine |
20 micrograms per day
decreases over time |
| gptkbp:propagationMethod |
intrauterine
|
| gptkbp:regulatoryCompliance |
CE mark
TGA_approval Health_Canada_approval |
| gptkbp:relatedPatent |
gptkb:Liletta
gptkb:Kyleena Skyla |
| gptkbp:researchFocus |
user satisfaction
long-term effects comparative effectiveness adverse effects monitoring |
| gptkbp:runnerUp |
annual check-ups
|
| gptkbp:setIn |
after childbirth
during menstrual period after abortion |
| gptkbp:sideEffect |
headaches
breast tenderness acne irregular bleeding |
| gptkbp:type |
hormonal IUD
|
| gptkbp:usedFor |
contraception
treatment of heavy menstrual bleeding |
| gptkbp:userDemographics |
women of reproductive age
postpartum women women seeking long-term contraception women with heavy menstrual bleeding |